Rallybio has commenced an open-label Phase II trial of RLYB212 in pregnant women at higher risk for HPA-1a alloimmunisation ...

Korro Bio has secured approvals in Australia to commence the Phase I/IIa trial of KRRO-110, aimed at treating AATD.

ImmunityBio has partnered with nCartes to automate and expedite the data fulfilment process for clinical trials.

Dubbed Nubeqa but known generically as darolutamide, the treatment comes in combination with androgen deprivation therapy ...

Endeavor has dosed the first subject in the randomised Phase IIb WHISTLE-PF trial of ENV-101 (taladegib) for IPF.

The FDA has released a draft of new guidance addressing common FAQs about the development of potential CGT treatments.

Puma Biotechnology has commenced the Phase II trial, ALISCA-Breast1, to evaluate oral alisertib, a selective inhibitor of ...

GigaGen, a subsidiary of Grifols, has commenced a Phase I trial, with the first patient receiving a dose of GIGA-2339 aimed ...

Emmecell has published positive topline outcomes from a Phase I trial of EO2002, its nonsurgical cell therapy candidate for ...

New data from Barinthus Bio's HBV003 trial has demonstrated durable HBsAG loss in participants with chronic hepatitis B.

Johnson & Johnson has reported positive outcomes from its Phase III trial of oral icotrokinra for treating plaque psoriasis.

Melt Pharmaceuticals has reported results from its Phase III trial of MELT-300 non-opioid sedation tablet for cataract ...